צמיחת הכנסות ב-12 חודשים נגררים: UroGen Pharma Corp (URGN)

The Israeli biopharmaceutical sector is exposed to severe military and geopolitical risks, which could destabilize the operations of UroGen Pharma Ltd. (URGN). The TTM revenue growth trend illustrates the current market valuation, where 159.00 expresses the metric's value today. UroGen Pharma Ltd. (URGN) generates revenue from the sale of patented therapies for kidney and bladder tumors, while its innovative hydrogel has established the brand's impeccable authority among physicians.
UroGen Pharma - פילוחים אנליטיים ומדדי מפתח (URGN)

Year-over-year (TTM) sales growth reflects the market expansion of UroGen Pharma Ltd. (URGN), transforming daily revenue updates into a continuous trend of annual performance. This indicator measures the percentage deviation of the current trailing twelve months from the previous period, which, combined with the recruitment of experienced oncology sales managers, confirms the company's ability to convert scientific potential into sustainable commercial success.